Please wait
S-4 S-4 EX-FILING FEES 0001728328 InMed Pharmaceuticals Inc. N/A N/A 0001728328 2026-07-02 2026-07-02 0001728328 1 2026-07-02 2026-07-02 0001728328 2 2026-07-02 2026-07-02 0001728328 3 2026-07-02 2026-07-02 iso4217:USD xbrli:pure xbrli:shares

Calculation of Filing Fee Tables

S-4

InMed Pharmaceuticals Inc.

Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable

Security Type

Security Class Title

Fee Calculation or Carry Forward Rule

Amount Registered

Proposed Maximum Offering Price Per Unit

Maximum Aggregate Offering Price

Fee Rate

Amount of Registration Fee

Carry Forward Form Type

Carry Forward File Number

Carry Forward Initial Effective Date

Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward

Newly Registered Securities
Fees to be Paid 1 Equity Common Stock, par value $0.0001 per share Other 451,779,258 $ 15,059.31 0.0001381 $ 2.08
Fees to be Paid 2 Equity Warrants to purchase shares of Common Stock Other 25,894,365 $ 0.00 0.0001381 $ 0.00
Fees to be Paid 3 Equity Series A Non-Voting Convertible Preferred Stock, par value $0.0001 per share Other 41,212 $ 0.00 0.0001381 $ 0.00
Fees Previously Paid
Carry Forward Securities
Carry Forward Securities

Total Offering Amounts:

$ 15,059.31

$ 2.08

Total Fees Previously Paid:

$ 0.00

Total Fee Offsets:

$ 0.00

Net Fee Due:

$ 2.08

Offering Note

1

(1) Prior to the completion of the merger described below InMed Pharmaceuticals Inc., a corporation organized under the laws of the Province of British Columbia, Canada (the "Canadian Corporation"), will redomesticate from the Province of British Columbia, Canada to the State of Nevada by continuation under the laws of British Columbia and domestication under the laws of the State of Nevada (the "Redomestication"), pursuant to which the Canadian Corporation will become a corporation organized under the laws of the State of Nevada (the "Nevada Corporation") and equity interests of the Canadian Corporation will be automatically converted by operation of law into corresponding equity interests of the Nevada Corporation, including that each outstanding common share, no par value (the "InMed Common Shares"), of the Canadian Corporation will be automatically converted by operation of law into one share of common stock, par value $0.0001 per share (the "InMed Common Stock"), of the Nevada Corporation. All securities being registered hereby give effect to the Redomestication, and the term "InMed" shall mean the Canadian Corporation before the Redomestication and the Nevada Corporation following the Redomestication. This row relates to shares of InMed Common Stock issuable to holders of common stock, $0.0001 par value per share, of Mentari Therapeutics, Inc., a Delaware corporation ("Mentari"), and other Mentari security holders in the proposed merger of Indigo Merger Sub Corp., a Delaware corporation and a direct, wholly owned subsidiary of InMed, with and into Mentari, with Mentari surviving the merger, and as part of the same overall transaction, Mentari will merge with and into Indigo Merger Sub II, LLC, a Delaware limited liability company and a wholly owned subsidiary of InMed, with Indigo Merger Sub II, LLC continuing as a wholly owned subsidiary of InMed and the surviving entity of the merger. The number of shares of InMed Common Stock to be registered includes the estimated maximum number of shares of InMed Common Stock that are expected to be issued (or become issuable) pursuant to the merger, without taking into account the effect of a reverse stock split of InMed Common Shares (the "Reverse Stock Split"), assuming an estimated pre-split exchange ratio (which is subject to adjustment prior to the closing of the merger) of approximately 2.0606 shares of InMed Common Stock for each outstanding share of common stock of Mentari. The issuances of (i) all shares of InMed Common Stock in exchange for each share of Mentari Common Stock and Mentari Series A Preferred Stock, (ii) all InMed Warrants in exchange for Mentari Warrants (including Mentari Pre-Funded Warrants issued in the Mentari Pre-Closing Financing), (iii) all shares of InMed Series A Preferred Stock in exchange for shares of Mentari Series Seed Preferred Stock, (iv) all options to purchase shares of InMed Common Stock in exchange for options to purchase shares of Mentari Common Stock, (v) all InMed RSUs in exchange for Mentari RSUs, (vi) all shares of InMed Common Stock issuable upon exercise of InMed Warrants issued in exchange for Mentari Warrants, (vii) all shares of InMed Common Stock issuable upon conversion of shares of InMed Series A Preferred Stock issued in exchange for Mentari Series Seed Preferred Stock, (viii) all shares of InMed Common Stock issuable upon exercise of options to purchase shares of InMed Common Stock issued in exchange for Mentari Options, and (ix) all shares of InMed Common Stock issuable upon settlement of InMed RSUs issued in exchange for Mentari RSUs, are intended to be covered by this registration statement on Form S-4. In accordance with Rule 416 under the Securities Act of 1933, as amended (the "Securities Act"), this registration statement shall be deemed to cover any securities that may from time to time be offered or issued resulting from forward or reverse stock splits, stock dividends or similar transactions. (2) Estimated solely for purposes of calculating the registration fee in accordance with Rule 457(f)(2) of the Securities Act. Mentari is a private company, no market exists for its securities, and it has an accumulated capital deficit. Therefore, the proposed maximum aggregate offering price for the shares expected to be issued pursuant to the merger is one-third of the aggregate par value of the Mentari securities expected to be exchanged in the proposed merger.

2

Consists of InMed Warrants issued in the merger in exchange for Mentari Warrants, without taking into account the effect of the Reverse Stock Split, assuming an estimated pre-split exchange ratio (which is subject to adjustment prior to the closing of the merger) of approximately 2.0606 shares of InMed Common Stock for each outstanding share of common stock of Mentari. The registration fee with respect to the InMed Warrants has been allocated to the underlying shares of InMed Common Stock issuable upon exercise of such InMed Warrants, as described in footnote (1).

3

Consists of all shares of InMed Series A Preferred Stock convertible into shares of InMed Common Stock (at a ratio of 1,000 shares of InMed Common Stock per one share of InMed Series A Preferred Stock) issued in the merger in exchange for shares of Mentari Series Seed Preferred Stock, without taking into account the effect of the Reverse Stock Split, assuming an estimated pre-split exchange ratio (which is subject to adjustment prior to the closing of the merger) of approximately 2.0606 shares of InMed Common Stock for each outstanding share of common stock of Mentari. The registration fee with respect to the shares of InMed Series A Preferred Stock has been allocated to the underlying shares of InMed Common Stock issuable upon conversion of such shares of InMed Series A Preferred Stock, as described in footnote (1).
Table 2: Fee Offset Claims and Sources ☑Not Applicable
Registrant or Filer Name Form or Filing Type File Number Initial Filing Date Filing Date Fee Offset Claimed Security Type Associated with Fee Offset Claimed Security Title Associated with Fee Offset Claimed Unsold Securities Associated with Fee Offset Claimed Unsold Aggregate Offering Amount Associated with Fee Offset Claimed Fee Paid with Fee Offset Source
Rules 457(b) and 0-11(a)(2)
Fee Offset Claims
Fee Offset Sources
Rule 457(p)
Fee Offset Claims
Fee Offset Sources
Table 3: Combined Prospectuses ☑Not Applicable

Security Type

Security Class Title

Amount of Securities Previously Registered

Maximum Aggregate Offering Price of Securities Previously Registered

Form Type

File Number

Initial Effective Date